· Per S. Thoresen as re-elected Board Member
· Ingrid Leisner as re-elected Board Member
· Øystein Stray Spetalen as new Board Member
· Kristin Hellebust as new Board Member
Further, the proposal from the Nomination Committee is that the following new Nomination Committee is elected at the extraordinary general meeting on 9 September 2016:
· Jan Frode Andersen as newly elected Chairman of the Nomination Committee
· Stig Myrseth as re-elected Member of Nomination Committee
· Birger Sørensen as re-elected Member of Nomination Committee
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
Per S. Thoresen, Chairman of the Board of Directors, +47 906 14 620
Unni Hjelmaas, Acting CEO, +47 915 19 651, email@example.com
Proposal from Nomination Committee_20160831
This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Bionor Pharma ASA via GlobeNewswire
Last updated on: 01/09/2016